COMP <GO>
PROF vs PDEX // RSI-14 & 200D SMA MOMENTUM
Profound Medical Corp. (NASDAQ) VS. Pro-Dex Inc. (NASDAQ) • 15-METRIC TALLY: PROF 4
— PDEX 5
▲ RSI-14 & 200D SMA MOMENTUM LEADER: PROF
LAST: $5.86 (+1.38%) • MKT CAP: $214.1M
rsi-technicals
58.7
LAST: $61.60 (-2.52%) • MKT CAP: $199.2M
rsi-technicals
38.5
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PROF VS. PDEX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PROF | PDEX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.80% | 29.30% | +41.50 | PROF | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 23.20% | -58.20 | PDEX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -17.93% | -1.47% | -16.46 | PDEX | /fcf-yield <GO> |
| Operating Margin | -60.00% | 16.10% | -76.10 | PDEX | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 13.50% | -73.50 | PDEX | /net-margins <GO> |
| Revenue Growth (YoY) | 65.30% | 23.70% | +41.60 | PROF | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.97 | 9.08 | -3.11 | PDEX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 58.7 | 38.5 | +20.18 | PROF | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $214.1M | $199.2M | $14.9M | PROF | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PROF REV | PDEX REV | PROF GROSS % | PDEX GROSS % | PROF FCF | PDEX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $16.1M | $66.6M | 70.8% | 29.3% | -$38.4M | -$2.9M |
| FY 2024 | $9.7M | $53.8M | 72.2% | 27.0% | -$23.5M | $6.2M |
| FY 2023 | $5.9M | $46.1M | — | — | -$22.6M | $5.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PROF // BETA —
PDEX // BETA —